Efficacy and safety of fresh fibroblast allografts in the treatment of diabetic foot ulcers

Seung-Kyu Han, Hyon Surk Kim, Woo-Kyung Kim

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

BACKGROUND AND OBJECTIVE Various types of allogenic skin substitutes composed of cryopreserved keratinocytes, fibroblasts, or both have been used for treatments of diabetic foot ulcers, but the effects have generally not been dramatic because cryopreservation impairs cell activities. The purpose of the study was to evaluate the use of non-cryopreserved fresh human fibroblast allografts in treating diabetic foot ulcers. MATERIALS AND METHODS Human dermal fibroblasts from healthy teenagers were cultured and applied over the foot ulcers of 37 patients with diabetes. Control treatment was performed in 18 patients. Eight weeks after treatment, the percentages of complete healing, mean healing times, and patient satisfaction were compared, with follow-up ranging from 6 to 40 months. RESULTS Our study showed that 83.8% of the treated group and 50.0% of the control group experienced complete healing. The times required for complete healing were 30.9±10.1 and 47.2±7.8 days in the treated and control groups, respectively. Patient satisfaction with fresh fibroblast treatment was also superior to satisfaction with the conventional method (mean scores: 8.0±1.0 and 4.9±1.4, respectively). No adverse events related to the study treatment occurred. CONCLUSION The use of fresh human fibroblast allografts was found to be a safe and effective treatment for diabetic foot ulcers.

Original languageEnglish
Pages (from-to)1342-1348
Number of pages7
JournalDermatologic Surgery
Volume35
Issue number9
DOIs
Publication statusPublished - 2009 Sep 1

Fingerprint

Diabetic Foot
Allografts
Fibroblasts
Safety
Patient Satisfaction
Therapeutics
Artificial Skin
Foot Ulcer
Control Groups
Cryopreservation
Keratinocytes
Skin

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

Efficacy and safety of fresh fibroblast allografts in the treatment of diabetic foot ulcers. / Han, Seung-Kyu; Kim, Hyon Surk; Kim, Woo-Kyung.

In: Dermatologic Surgery, Vol. 35, No. 9, 01.09.2009, p. 1342-1348.

Research output: Contribution to journalArticle

@article{c0ad6440bfa941b2aac9e5e1abf4aec9,
title = "Efficacy and safety of fresh fibroblast allografts in the treatment of diabetic foot ulcers",
abstract = "BACKGROUND AND OBJECTIVE Various types of allogenic skin substitutes composed of cryopreserved keratinocytes, fibroblasts, or both have been used for treatments of diabetic foot ulcers, but the effects have generally not been dramatic because cryopreservation impairs cell activities. The purpose of the study was to evaluate the use of non-cryopreserved fresh human fibroblast allografts in treating diabetic foot ulcers. MATERIALS AND METHODS Human dermal fibroblasts from healthy teenagers were cultured and applied over the foot ulcers of 37 patients with diabetes. Control treatment was performed in 18 patients. Eight weeks after treatment, the percentages of complete healing, mean healing times, and patient satisfaction were compared, with follow-up ranging from 6 to 40 months. RESULTS Our study showed that 83.8{\%} of the treated group and 50.0{\%} of the control group experienced complete healing. The times required for complete healing were 30.9±10.1 and 47.2±7.8 days in the treated and control groups, respectively. Patient satisfaction with fresh fibroblast treatment was also superior to satisfaction with the conventional method (mean scores: 8.0±1.0 and 4.9±1.4, respectively). No adverse events related to the study treatment occurred. CONCLUSION The use of fresh human fibroblast allografts was found to be a safe and effective treatment for diabetic foot ulcers.",
author = "Seung-Kyu Han and Kim, {Hyon Surk} and Woo-Kyung Kim",
year = "2009",
month = "9",
day = "1",
doi = "10.1111/j.1524-4725.2009.01239.x",
language = "English",
volume = "35",
pages = "1342--1348",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Efficacy and safety of fresh fibroblast allografts in the treatment of diabetic foot ulcers

AU - Han, Seung-Kyu

AU - Kim, Hyon Surk

AU - Kim, Woo-Kyung

PY - 2009/9/1

Y1 - 2009/9/1

N2 - BACKGROUND AND OBJECTIVE Various types of allogenic skin substitutes composed of cryopreserved keratinocytes, fibroblasts, or both have been used for treatments of diabetic foot ulcers, but the effects have generally not been dramatic because cryopreservation impairs cell activities. The purpose of the study was to evaluate the use of non-cryopreserved fresh human fibroblast allografts in treating diabetic foot ulcers. MATERIALS AND METHODS Human dermal fibroblasts from healthy teenagers were cultured and applied over the foot ulcers of 37 patients with diabetes. Control treatment was performed in 18 patients. Eight weeks after treatment, the percentages of complete healing, mean healing times, and patient satisfaction were compared, with follow-up ranging from 6 to 40 months. RESULTS Our study showed that 83.8% of the treated group and 50.0% of the control group experienced complete healing. The times required for complete healing were 30.9±10.1 and 47.2±7.8 days in the treated and control groups, respectively. Patient satisfaction with fresh fibroblast treatment was also superior to satisfaction with the conventional method (mean scores: 8.0±1.0 and 4.9±1.4, respectively). No adverse events related to the study treatment occurred. CONCLUSION The use of fresh human fibroblast allografts was found to be a safe and effective treatment for diabetic foot ulcers.

AB - BACKGROUND AND OBJECTIVE Various types of allogenic skin substitutes composed of cryopreserved keratinocytes, fibroblasts, or both have been used for treatments of diabetic foot ulcers, but the effects have generally not been dramatic because cryopreservation impairs cell activities. The purpose of the study was to evaluate the use of non-cryopreserved fresh human fibroblast allografts in treating diabetic foot ulcers. MATERIALS AND METHODS Human dermal fibroblasts from healthy teenagers were cultured and applied over the foot ulcers of 37 patients with diabetes. Control treatment was performed in 18 patients. Eight weeks after treatment, the percentages of complete healing, mean healing times, and patient satisfaction were compared, with follow-up ranging from 6 to 40 months. RESULTS Our study showed that 83.8% of the treated group and 50.0% of the control group experienced complete healing. The times required for complete healing were 30.9±10.1 and 47.2±7.8 days in the treated and control groups, respectively. Patient satisfaction with fresh fibroblast treatment was also superior to satisfaction with the conventional method (mean scores: 8.0±1.0 and 4.9±1.4, respectively). No adverse events related to the study treatment occurred. CONCLUSION The use of fresh human fibroblast allografts was found to be a safe and effective treatment for diabetic foot ulcers.

UR - http://www.scopus.com/inward/record.url?scp=69949162125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949162125&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4725.2009.01239.x

DO - 10.1111/j.1524-4725.2009.01239.x

M3 - Article

VL - 35

SP - 1342

EP - 1348

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 9

ER -